Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Pancreas Ductal Adenocarcinoma: early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Pancreas Ductal Adenocarcinoma: 2 US clinical trials tracked, none currently recruiting.

Pancreas Ductal Adenocarcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Academic Thoracic Oncology Medical Investigators Consortium, running 1 of these trials.

Enrollment posture brief

Registry condition pancreas-ductal-adenocarcinoma

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Pancreas Ductal Adenocar (th…0%
Open-enrollment share among volume-matched conditions near Pancreas Ductal Adenocarcinoma

Pancreas Ductal Adenocarcinoma has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pancreas Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pancreas Ductal Adenocarcinoma is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Pancreas Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Abdominal imaging Other
1 trials
Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score Other
1 trials
Nab paclitaxel Drug
1 trials
Gemcitabine Drug
1 trials

US sites by state

Facility locations filed on Pancreas Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.

Texas 1 trials
New York 1 trials
Colorado 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pancreas Ductal Adenocarcinoma page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreas Ductal Adenocarcinoma condition card totals 2 registered trials; most-linked intervention Abdominal imaging; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.